ID   CWR22Rv1-AR-EK
AC   CVCL_WK44
SY   CWR22Rv1-Androgen Receptor-Exon Knockout
DR   cancercelllines; CVCL_WK44
DR   Wikidata; Q93464997
RX   PubMed=31006810;
CC   Population: Caucasian.
CC   Characteristics: Has lost the ability to express full-length AR (FL-AR), but retains that of expressing alternatively spliced forms of the AR termed AR variants (AR-Vs).
CC   Characteristics: Using CRISPR/Cas9 a stop codon was introduced downstream of the DNA-binding domain in exon 5 of the AR gene.
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
ST   Source(s): PubMed=31006810
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,12
ST   D16S539: 12
ST   D21S11: 30
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 15,21
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1045 ! 22Rv1
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 05-10-23; Version: 8
//
RX   PubMed=31006810; DOI=10.1093/nar/gkz286;
RA   Kounatidou E., Nakjang S., McCracken S.R.C., Dehm S.M., Robson C.N.,
RA   Jones D., Gaughan L.;
RT   "A novel CRISPR-engineered prostate cancer cell line defines the AR-V
RT   transcriptome and identifies PARP inhibitor sensitivities.";
RL   Nucleic Acids Res. 47:5634-5647(2019).
//